Hepatocellular carcinoma (HCC) is the most common type of liver tumors. There is only one
chemodrug for treatment called sorafenib that is an effective multikinase inhibitor. However …

Sorafenib is a small‑molecule multi‑kinase inhibitor approved by FDA as an oral agent for
the treatment of hepatocellular carcinoma (HCC) and renal cell carcinoma. However …

Sorafenib is presently the only effective therapy in advanced hepatocellular carcinoma
(HCC). Because most anticancer drugs act, at least in part, through the generation of …

As an effective targeted therapy for advanced hepatocellular carcinoma (HCC), sorafenib
resistance has been frequently reported in recent years, with the activation of autophagy by …

An antimalarial medication, artesunate (Art), has exhibited promising anticancer effects with
excellent tolerability in various types of cancer, suggesting that it has the potential to be used …

The present study aimed to evaluate the effects of amentoflavone on sorafenib‑induced
apoptosis in sorafenib‑resistant hepatocellular carcinoma (HCC) cells. The sorafenib …

The multikinase inhibitor sorafenib is the only effective drug in advanced cases of
hepatocellular carcinoma (HCC). However, response differs among patients and …

Sorafenib is an orally administered multikinase inhibitor that exhibits anti-angiogenic and
anti-tumor activity. Sorafenib is also known to bind to protein (> 99.5%), suggesting protein …

Introduction: Metastatic breast cancer has poor prognosis due to limited therapeutic options.
Protein kinase dysregulations have a major role in breast cancer progression and …

The combination of anti-cancer drugs with nutritional factors is a potential strategy for
improving the efficacy of chemotherapy, particularly for hepatocellular carcinoma because …